-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2021 to 2023.
- Elite Pharmaceuticals Inc /Nv/ Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $18.2K.
- Elite Pharmaceuticals Inc /Nv/ annual Deferred Income Tax Expense (Benefit) for 2023 was -$20M.
Deferred Income Tax Expense (Benefit), Annual (USD)